Novocure Secures New $400M Non-Dilutive Debt Financing From Pharmakon
Novocure Secures New $400M Non-Dilutive Debt Financing From Pharmakon
Novocure從Pharmakon獲得新的4億美元非稀釋性債務融資
Use of proceeds to fund working capital needs stemming from Novocure's anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure's convertible notes
使用所得款項爲Novocure預計在非小細胞肺癌領域上市所產生的營運資金需求提供資金,並在到期時結算Novocure的可轉換票據
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。